COLORADO

Apr. 14, 2021

 

Colorado pauses use of Johnson & Johnson COVID-19 vaccine after joint FDA and CDC announcement

 

REMOTE, (April 13, 2021): In response to the joint CDC and FDA announcement and out of an abundance of caution, today the Colorado Department of Public Health and Environment (CDPHE) and the Colorado Joint Vaccine Task Force are alerting providers to temporarily pause use of the Johnson & Johnson (Janssen) COVID-19 vaccine. 

Federal health officials recommended temporarily suspending use of the vaccine after reviewing reports of six individuals in the U.S. who got rare and severe blood clots after receiving the vaccine. The federal government is allowing states to determine whether to pause use, and CDPHE is requiring providers to stop administration of the Johnson & Johnson (Janssen) vaccine until additional information becomes available. One of the reasons the FDA and CDC are recommending this pause is to ensure health care providers are aware of these potential but rare adverse events and can respond accordingly. The treatment for these types of blood clots is not the common treatment and thus time is needed to make sure healthcare providers know how to recognize and treat these rare occurrences. 

COVID-19 vaccine safety and the health and safety of all Coloradans is a top priority. These adverse events appear to be extremely rare. Individuals who received the Johnson & Johnson (Janssen) vaccine more than a month ago are at very low risk of serious side effects. Anyone who received the Johnson & Johnson (Janssen) vaccine within the last three weeks and who develops severe headache, abdominal pain, leg pain, or shortness of breath should contact their health care provider. These symptoms are different from the flu-like symptoms people may experience after receiving a COVID-19 vaccine. Healthcare providers should report any adverse events to the Vaccine Adverse Event Reporting System (VAERS).

“In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given,” the FDA and CDC stated in a joint statement.  

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will hold an emergency meeting Wednesday, April 14, to further review the cases and assess their potential significance, and the Food and Drug Administration will continue to investigate. The state will share additional information on how this affects Coloradans as soon as it becomes available. 

The Johnson & Johnson (Janssen) vaccine makes up only a small portion of Colorado’s weekly vaccine allocation. This week, for example, the state’s Johnson & Johnson (Janssen) allocation is 9,700, compared to nearly 280,000 doses of Pfizer and Moderna the state expects to receive this week. Most vaccine clinics will not be significantly affected. 

Anyone scheduled to receive the Johnson & Johnson (Janssen) vaccine will either receive the Pfizer or Moderna vaccine instead, or the vaccine provider will contact them to reschedule their appointment once FDA and CDC release additional information. 

The state’s mobile vaccination buses, which have been administering only the Johnson & Johnson (Janssen) vaccine, are canceled today and Wednesday. More information will be provided when it becomes available. 

Providers who already have a Johnson & Johnson (Janssen) vaccine supply should keep it and continue to maintain proper storage

Continue to stay up to date by visiting covid19.colorado.gov.

 

###

 

Colorado suspende el uso de la vacuna contra el COVID-19 de Johnson & Johnson posterior al anuncio conjunto de la FDA y los CDC

REMOTO, (13 de abril de 2021): En respuesta al anuncio conjunto de los CDC y la FDA, y tomando la debida precaución, hoy el Departamento de Salud Pública y Medio Ambiente de Colorado (CDPHE, por sus siglas en inglés) y el Grupo de Trabajo Conjunto de Vacunas de Colorado están alertando a los proveedores para que suspendan temporalmente el uso de la vacuna contra el COVID-19 de Johnson & Johnson (Janssen).

Los funcionarios federales de salud recomendaron suspender temporalmente el uso de la vacuna después de revisar los reportes de seis personas en los EE.UU. que desarrollaron coágulos de sangre inusuales y graves después de recibir la vacuna. El gobierno federal está permitiendo que los estados determinen si suspenden su uso, y el CDPHE está requiriendo que los proveedores detengan la administración de la vacuna de Johnson & Johnson (Janssen) hasta que información adicional esté disponible. Una de las razones por las que la FDA y los CDC están recomendando esta pausa es para asegurar que los proveedores de atención médica sean conscientes de estos posibles, pero inusuales, eventos adversos, y puedan responder en consecuencia. El tratamiento para este tipo de coágulos no es el tratamiento común, por lo que se necesita tiempo para asegurar que los proveedores de atención médica sepan cómo reconocer y tratar estos eventos inusuales.

La seguridad de la vacuna contra el COVID-19 es la mayor prioridad. Estos eventos adversos parecen ser extremadamente inusuales. Las personas que recibieron la vacuna de Johnson & Johnson (Janssen) hace más de un mes tienen un riesgo muy bajo de tener efectos secundarios graves. Cualquier persona que haya recibido la vacuna de Johnson & Johnson (Janssen) en las últimas tres semanas y que desarrolle dolor de cabeza intenso, dolor abdominal, dolor en las piernas o dificultad para respirar debe ponerse en contacto con su proveedor de atención médica. Estos síntomas son diferentes de los síntomas similares a los de la gripe que las personas pueden experimentar después de recibir la vacuna contra el COVID-19. Los proveedores de atención médica deben reportar cualquier evento adverso al Sistema de Notificación en caso de Efectos Adversos a la Vacuna (VAERS, por sus siglas en inglés).

"En estos casos, se observó un tipo de coágulo sanguíneo llamado trombosis del seno venoso cerebral (CVST, por sus siglas en inglés) en combinación con niveles bajos de plaquetas de la sangre (trombocitopenia). Los seis casos ocurrieron en mujeres de entre 18 y 48 años, y los síntomas sucedieron entre 6 y 13 días después de la vacunación. El tratamiento para este tipo específico de coágulo sanguíneo es diferente del que normalmente se administra. Usualmente, un medicamento anticoagulante llamado heparina es utilizado para tratar los coágulos sanguíneos. En este caso, la administración de heparina puede ser peligrosa, y es necesario administrar tratamientos alternativos", anunciaron la FDA y los CDC en un informe conjunto. 

El Comité Asesor sobre Prácticas de Inmunización de los Centros para el Control y la Prevención de Enfermedades llevará a cabo una reunión de emergencia el miércoles 14 de abril para seguir revisando los casos y evaluar su posible importancia, y la Administración de Alimentos y Medicamentos de los Estados Unidos seguirá investigando. El estado compartirá información adicional sobre cómo esto afecta a los habitantes de Colorado, tan pronto esté disponible.

La vacuna de Johnson & Johnson (Janssen) conforma sólo una pequeña parte de la asignación semanal de vacunas de Colorado. Esta semana, por ejemplo, la asignación semanal para el estado es de 9,700, en comparación con las casi 280,000 dosis de Pfizer y Moderna que el estado espera recibir esta semana. La mayoría de las clínicas de vacunación no se verán afectadas de manera significativa. 

Cualquier persona que tenga programado recibir la vacuna de Johnson & Johnson (Janssen) recibirá la vacuna de Pfizer o Moderna en su lugar, o el proveedor de la vacuna se pondrá en contacto con ellos para reprogramar su cita una vez que la FDA y los CDC publiquen información adicional. 

Los autobuses móviles de vacunación del estado, los cuales han estado administrando sólo la vacuna de Johnson & Johnson (Janssen), han sido cancelados hoy. Se proporcionará más información cuando esté disponible. 

Los proveedores que ya tienen un suministro de vacunas de Johnson & Johnson (Janssen) deben conservarlo y seguir manteniendo un almacenamiento adecuado.

Continúe manteniéndose informado visitando covid19.colorado.gov.

 

Apr. 14, 2021

Attorney General Phil Weiser testifies in support of legislation to keep firearms out of the hands of domestic abusers

April 13, 2021 (DENVER)—Attorney General Phil Weiser today testified before the Colorado House Judiciary Committee in support of House Bill 21-1255, legislation that would protect domestic violence survivors by helping keep firearms out of the hands of domestic abusers.

The Domestic Violence Fatality Review Board, which Weiser chairs, found that 70 people died in domestic violence incidents in 2019 in Colorado, and gunshot wounds accounted for nearly two-thirds of those deaths. In a report released in 2020, the board recommended prohibiting domestic violence perpetrators from possessing firearms.

House Bill 21-1255 addresses this recommendation by expanding upon and clarifying procedures for the relinquishment of firearms by someone who has a domestic violence-related protection order issued against them.

“Limiting access to firearms for those subject to domestic violence-related protection orders is a commonsense health and safety measure,” said Weiser. “By clarifying requirements already in place, this bill takes important steps to help ensure that the firearm relinquishment process is fair, straightforward, and can help save lives of domestic violence survivors in our state.”

In 2013, the General Assembly moved to protect the safety of survivors of domestic violence by passing Senate Bill 13-197. That bill required some domestic violence offenders who are subject to a protection order stemming from an act of domestic or intimate partner violence to relinquish their firearms and refrain from possessing or purchasing firearms for the duration of the order. Since then, however, stakeholders identified aspects of the law in need of clarification, as captured in the Review Board’s 2019 report.

House Bill 21-1255 clarifies how and when respondents and defendants must act to comply with the relinquishment requirement, and specifies the courts’ role in monitoring for compliance, making the process simpler for courts, respondents, and law enforcement to navigate.

The bill also closes the so-called “boyfriend loophole” by clarifying that the duty to relinquish firearms following a protective order applies not only to current and former spouses and cohabitants, but also to current and former unmarried couples. This extends current protections to cover all intimate partners subject to domestic violence protection orders, regardless of marital status.

The bill also prohibits those subject to the relinquishment requirement from transferring firearms to a private party living in the same residence. This provision is consistent with the core purpose of the relinquishment requirement—keeping firearms out the hands of domestic abusers who are subject to a protection order.

###

Media Contact
Lawrence Pacheco
Director of Communications
(720) 508-6553 office | (720) 245-4689 cell